Insilico Medicine has successfully integrated cutting-edge generative AI models into its platform, achieving significant increases in accuracy and speed. The company's AI-powered solutions have shown promising results in preclinical candidates and Phase II clinical trials.
Insilico Medicine has developed an innovative platform using generative AI to discover novel molecules. The company has nominated over 20 preclinical candidates and received IND clearance for 10 molecules.
Alex Zhavoronkov, Insilico Medicine's founder and CEO, was named Highly Cited Researchers of 2024. He has published over 40 peer-reviewed research papers, with a total H-index of 64, and led the development of Insilico's lead drug pipeline, ISM001-055.
Insilico Medicine has been selected by Fortune as one of the top AI innovators, leveraging its generative AI platform to develop novel drugs and treatments. The company's lead drug pipeline, ISM001-055, has shown promising results in Phase IIa trials, offering new hope for patients with idiopathic pulmonary fibrosis.
Insilico Medicine has received FDA clearance for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. ISM5939 demonstrated robust anti-tumor efficacy in preclinical studies and showed favorable safety profiles.
Pharma.AI Week will showcase the latest advancements in Insilico's generative AI platform, including PandaOmics and Science42, with expert speakers and hands-on demos. The event aims to empower researchers and scientists with tools for faster and more accurate discoveries.
The Phase IIa trial of ISM001-055 showed dose-dependent improvement in forced vital capacity (FVC) and percent predicted FVC, suggesting potential to slow or reverse disease progression. The treatment also demonstrated a favorable pharmacokinetics profile with minimal adverse events.
Insilico Medicine CEO Alex Zhavoronkov to discuss AI business potential and economic growth at Fortune Global Forum 2024. The company has developed a generative AI-powered platform that utilizes deep learning techniques for novel target discovery and molecular structure generation.
Insilico Medicine has entered into a revolving loan facility of up to US$100 million with HSBC, enabling the company's global expansion and AI-driven innovation in biotechnology. The credit line will support Insilico's proprietary novel drug discovery pipeline and its end-to-end diversified AI platform, Pharma.AI.
The collaboration utilized Insilico's generative biology AI platform, Pharma.AI, to identify a novel lead for treating oncology diseases. The joint R&D team addressed the druggability challenge of highly novel targets using novel scaffolds generated by Chemistry42.
A new study reveals TNIK's role in various diseases, including fibrosis, cancer, obesity, and Alzheimer's. The protein has been found to drive cancer cell proliferation and treatment resistance, while also regulating metabolic processes.
Nach0 was trained on diverse tasks, including natural language understanding, synthetic route prediction, and molecular generation. The model performed well on molecular tasks using molecular data and outperformed ChatGPT, making it a significant step toward unlocking the full potential of LLMs for drug discovery.
Insilico Medicine's lead compound demonstrates strong enzymatic activity, selectivity, and favorable ADME properties, as well as antitumor activity in various animal models. The company's generative AI-powered platform generated over 3,600 candidate molecules before identifying the promising lead compound.
Researchers at Insilico Medicine developed COSMIC, a new framework for molecular conformation space modeling that provides accurate insights into molecule positioning and activity. This enables faster and more efficient drug design decisions.
Researchers at Insilico Medicine have identified a new class of Polθ inhibitors featuring central scaffolding rings, designed using Chemistry42, with significant enzymatic and cellular potency. The discovery showcases the potential of AI in medicinal chemistry for precise molecular modifications.
Researchers at Insilico Medicine have developed a novel PTPN2/N1 inhibitor with improved oral absorption and robust antitumor efficacy using the company's generative AI engine. The new compound demonstrates enhanced biological activities compared to existing inhibitors, offering new treatment possibilities for cancer patients.
Researchers at Insilico Medicine developed QFASG, a quantum-assisted algorithm generating novel small-molecule structures from fragments. The tool successfully designed inhibitors for cancer-related proteins, showcasing its potential in accelerating drug discovery and development.
Researchers used generative AI to design a lead molecule for treating fibrosis, a biological process associated with aging. The compound, INS018_055, demonstrated significant efficacy in preclinical studies and showed promising results in clinical trials, accelerating drug discovery and providing new therapeutic options.
PandaOmics uses advanced AI algorithms to process vast quantities of diverse data, performing gene and pathway analysis and target predictions. The platform has been extensively validated in multiple therapeutic areas, including oncology, inflammation, and immunology.
Researchers developed a framework for standardizing biomarker development and validation to improve the prediction of age-related health outcomes. The study highlights the need for expanded focus on functional decline, frailty, chronic disease, and disability, and calls for harmonization of omic data to enhance reliability.
Insilico Medicine has discovered a novel PHD inhibitor for treating anemia using its AI-powered generative chemistry platform Chemistry42. The compound demonstrated favorable ADMET and PK profiles in animal models, showing promise for further investigations.
Researchers at Insilico Medicine have identified MYT1 as a promising therapeutic target for breast and gynecological cancers. A series of novel, potent, and highly selective inhibitors specifically targeting MYT1 were discovered using AI-driven generative biology and chemistry engine.
Researchers identified a promising dual-purpose target, KDM1A, using AI analysis of transcriptomic data from 16,740 healthy samples and 11,303 tumors. KDM1A was found to significantly extend lifespan in Caenorhabditis elegans and has anti-cancer activities established in preclinical and clinical studies.
Insilico Medicine has identified 9 potential dual-purpose targets against aging and 14 major age-related diseases using Microsoft BioGPT. The proposed genes include CCR5 and PTH, which have not been previously correlated to the aging process.
Researchers identified potential therapeutic targets for Alzheimer's disease and other conditions using a new approach combining AI-driven target identification with protein phase separation analysis. The study provides insights into the role of protein phase separation in human disease and its potential as a therapeutic target.
Insilico Medicine's inClinico platform uses generative AI to predict Phase II to Phase III clinical trial success with an accuracy of 79%. The tool has been validated in various studies and can provide valuable insights for investors and biotech/pharma companies.
Researchers at Insilico Medicine discovered novel inhibitors for salt-inducible kinase 2 (SIK2), a potential target for anti-inflammation and anti-cancer therapy. The findings were published in the July 13 edition of Bioorganic & Medicinal Chemistry, demonstrating the power of Insilico's Pharma.AI platform.
The study evaluates recent research on artificial intelligence-generated molecular structures from the perspective of medicinal chemists, recommending guidelines for assessing novelty and validity. Insilico Medicine's recommendations aim to improve the process of generating and evaluating novel AI-generated drugs.
Scientists used Insilico Medicine's generative AI platform to identify actionable drug targets for cystinosis and validate them in preclinical models. The study found that hyperactive mTOR signaling drives kidney tubular cell dysfunction, making it a targetable pathway.
Three high school students co-authored a paper using AI engine PandaOmics to discover new therapeutic targets for glioblastoma multiforme, a common and aggressive malignant brain tumor. The study identified three genes strongly correlated with both aging and glioblastoma as potential therapeutic targets.
Researchers utilized the Chemistry42 platform to generate novel molecular structures and identified a hit molecule for CDK20, a promising target for hepatocellular carcinoma. The platform's customizable reward function and generative models enabled efficient design and optimization of molecules.
Scientists used AI-driven PandaOmics platform to analyze gene expression datasets from DNA repair diseases, identifying biomarkers associated with treatment response. The study focused on genes that stratify cancer patients by survival outcomes, providing potential targets for personalized therapies.
Researchers at Insilico Medicine used their proprietary AI-driven target discovery engine, PandaOmics, to identify 17 high-confidence and 11 novel therapeutic targets for ALS. These targets were further validated in various model systems, including a c9ALS Drosophila model, and showed strong functional correlations to ALS. The study's ...
Researchers at Insilico Medicine have used AI to identify potential targets that are implicated in multiple age-related diseases and also play a role in the basic biology of aging. The study resulted in the identification of 69 high-confidence targets with potential high druggability.
Insilico Medicine will present its latest results in modern and next-generation AI for generative chemistry at ACS Spring 2021. The company's Chemistry42 platform facilitates the discovery of novel small molecule leads in several therapeutic areas, integrating AI techniques with computational and medicinal chemistry methods.
Insilico Medicine introduces Molecular Sets (MOSES), a benchmarking platform for generative chemistry models, enabling easy comparison and evaluation of new models against existing approaches. The platform provides a curated dataset, metrics, and baselines for assessing model performance.
Insilico Medicine will showcase its latest AI advancements in drug discovery and productive longevity at the Leveraging Intelligent Tech for Drug Development Forum. The company's work on AI-generated molecular structures, synthetic biological data, and clinical trial prediction has garnered significant attention and funding.
A new study discovered that GULP1 is a key regulator of the NRF2-KEAP1 signaling axis in urothelial carcinoma. GULP1 knockdown led to increased tumor growth and resistance to cisplatin treatment.
A new deep learning-based aging clock uses whole genome sequencing data from thousands of gut bacteria to predict human biological age. The study shows that the age of the host is a significant contributor to gut community dynamics, with microflora succession patterns associated with age progression.
Researchers developed a machine learning algorithm to predict six major clinical forms of drug-induced cardiac toxicity from gene expression data. The model demonstrated generalizability and was validated on an independent dataset, with potential applications in enhancing pharmaceutical industry safety evaluation.
Researchers at Insilico Medicine developed a new AI model that combines generative biology and chemistry to generate novel molecular structures for a desired transcriptional response. The Bidirectional Adversarial Autoencoder can be used for virtual screening, discovering new molecular structures and predicting transcriptional responses.
The company has proposed a new family of prior distributions: TRIP, which improves Fréchet Inception Distance for GANs and Evidence Lower Bound for VAEs. The model was experimentally validated in cells and animals, demonstrating its potential for accelerating drug discovery.
A new AI system, Generative Tensorial Reinforcement Learning (GENTRL), was used to generate six novel inhibitors of DDR1 kinase target in just 21 days. Four compounds showed activity in biochemical assays, and one lead candidate demonstrated favorable pharmacokinetics in mice.
Researchers at Insilico Medicine have developed a new molecular descriptor, MCE-18, which estimates molecular complexity and defines the evolution of small molecules in medicinal chemistry. The study reveals that modern drug development is becoming more qualitative and smarter, with higher degrees of 3D complexity.
Researchers call for new models to value human life data, allowing patients to own and profit from their health information. This shift could lead to increased engagement in the healthcare system, driven by blockchain technology and AI-based data analysis.
Researchers discovered a new candidate gene, unpaired 1, that contributes to lifespan regulation in Drosophila melanogaster. Overexpression of this gene increased lifespan in nervous tissue and fat body, but decreased lifespan in intestine.
A new study published by the Moskalev Lab has revealed how overexpressing the pro-longevity gene Gclc in Drosophila melanogaster leads to life extension and changes in the thorax's transcriptome, including genes involved in metabolism, immune system, and circadian rhythmicity.
Researchers from Peking University and Insilico Medicine are collaborating on AI-powered drug discovery methods, aiming to accelerate pharmaceutical research and development. The project will focus on various applications of AI in drug discovery, including target identification, compound generation, and personalized medicine.
A recent study published in Scientific Reports found that smokers demonstrate a higher aging ratio and are predicted to be twice as old as their chronological age compared to nonsmokers. The study used blood biochemistry and artificial intelligence to analyze the impact of smoking on biological age.
A recent paper by Insilico Medicine introduces deep learning for aging research, revealing age as a key biological feature that can be predicted using various data types. The study also outlines the potential applications of this technology, including personalized immunotherapies and vaccinations.